Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans

Archives of Ophthalmology
G Atma VemulakondaRussell N Van Gelder

Abstract

To determine the penetration of 1% voriconazole solution into the aqueous and vitreous following topical administration. A prospective nonrandomized study of 13 patients scheduled for pars plana vitrectomy surgery. Aqueous and vitreous samples were obtained and analyzed after topical administration of 1% voriconazole every 2 hours for 24 hours before surgery. Drug concentration quantitation was performed using high-performance liquid chromatography. The mean (SD) sampling time after topical administration of the last voriconazole dose was 24 (14) minutes. The mean (SD) voriconazole concentrations in the aqueous and vitreous were 6.49 (3.04) microg/mL and 0.16 (0.08) microg/mL, respectively. Aqueous concentrations exceeded the minimum inhibitory concentration at which 90% of isolates are inhibited (MIC(90)) for a wide spectrum of fungi and mold, including Aspergillus, Fusarium, and Candida species. Vitreous concentrations of voriconazole exceeded the MIC(90) for Candida albicans. Topically administered voriconazole achieves therapeutic concentrations in the aqueous of the noninflamed human eye for many fungi and molds and achieves therapeutic levels in the vitreous for Candida species. Topical voriconazole may be a useful agent ...Continue Reading

Citations

May 25, 2012·Middle East African Journal of Ophthalmology·Randa S Haddad, Georges M El-Mollayess
Jun 17, 2014·International Journal of Antimicrobial Agents·Chin Fen NeohDavid C M Kong
Mar 5, 2009·Antimicrobial Agents and Chemotherapy·Ying-Cheng ShenLi-Chen Wei
May 13, 2009·Antimicrobial Agents and Chemotherapy·Daoud Al-BadriyehDavid C M Kong
May 14, 2010·Clinical Ophthalmology·Daoud Al-BadriyehDavid C M Kong
Aug 7, 2010·Indian Journal of Ophthalmology·Vikas MittalP C Sharma
Apr 13, 2011·Archives of Ophthalmology·Sumitra S KhandelwalR Doyle Stulting
Jul 20, 2011·Antimicrobial Agents and Chemotherapy·Sang Beom HanWon Ryang Wee
Mar 17, 2009·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Sophie X DengDavid A Hollander
Jun 22, 2012·Infection·P TrokeO Lortholary
Apr 21, 2012·Journal of the American Veterinary Medical Association·Jonathan D PucketAmy J Rankin
Aug 20, 2011·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·A-K B MaierP Rieck
May 15, 2013·Biomedical Engineering Online·Robert KoprowskiEdward Wylęgała
Dec 2, 2009·Expert Opinion on Drug Metabolism & Toxicology·George R Thompson, James S Lewis
May 20, 2008·Ophthalmology·Charles C WykoffEduardo C Alfonso
Sep 3, 2009·Clinical & Experimental Ophthalmology·David LauDavid C M Kong
Sep 16, 2010·Veterinary Ophthalmology·Rachael A GrundonRobin G Stanley
Nov 26, 2015·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Akiko OgawaKazuo Tsubota
Mar 14, 2014·Journal of Chemotherapy·Melis PalamarOmur Ucakhan Gunduz
Apr 22, 2014·Ophthalmology·Catherine Q SunUNKNOWN Mycotic Ulcer Treatment Trial Group
Oct 21, 2010·Current Eye Research·Srinivasan SenthilkumariThirumurthy Velpandian
Oct 23, 2016·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Rusheng ChewMarion L Woods
Aug 24, 2016·Antimicrobial Agents and Chemotherapy·Chin Fen NeohDavid C M Kong
Apr 1, 2011·Journal of Clinical Microbiology·Brunella PosteraroMaurizio Sanguinetti
Aug 12, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Daoud Al-BadriyehRobert Fullinfaw
Mar 14, 2012·Cornea·Vikas Mittal, Ruchi Mittal
Aug 19, 2016·Cornea·Harshal Shrikant RathiMeenakshi Ravindran
Sep 8, 2011·International Ophthalmology Clinics·Han-Ying Peggy Chang, James Chodosh
May 21, 2013·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·C M Martín-NavarroJ Lorenzo-Morales
Nov 26, 2010·Clinical & Experimental Ophthalmology·Ritu AroraRavinder Kaur
Oct 24, 2019·Pharmaceutical Development and Technology·Zahra MohtashamiHamid Akbari Javar
Oct 28, 2019·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Marine RochePascal Odou
Apr 30, 2021·Indian Journal of Ophthalmology·Manali HazarikaSrinivasan Senthilkumari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.